Zheng Lei, Wang Zuoping, Li Yunxiang, Ge Si, Zeng Zhiqiang, Gan Lijian, Meng Chunyang, Li Kangsen
Department of Urology, Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College (University), Nanchong, Sichuan, China.
Department of Urology, School of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan, China.
Front Oncol. 2024 Dec 23;14:1469444. doi: 10.3389/fonc.2024.1469444. eCollection 2024.
This review assessed the prognostic significance of the systemic immune inflammation index (SII) in patients with urothelial carcinoma.
We performed a systematic review and cumulative meta-analysis of the primary outcomes according to the PRISMA criteria, and assessed study quality. Seven databases were searched: Embase, PubMed, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang, and SinoMed, from the creation of each database until October 2024.
The meta-analysis included 31 studies, including 14,437 patients with urothelial carcinoma. A low SII was significantly associated with better recurrence-free survival (RFS) (HR = 1.37, 95%CI (1.19, 1.56), P < 0.05), cancer-specific survival (CSS) (HR = 1.87, 95%CI (1.50, 2.34), P < 0.05), and overall survival (OS) (HR = 1.42, 95%CI (1.23, 1.64), P < 0.05). In addition, subgroup analysis found that higher SII was associated with poorer prognosis regardless of treatment regimen, tumor type, or SII cutoff, and that high SII was an important prognostic biomarker in the UC population.
A low SII may be associated with better RFS, CSS, and OS. The SII can be used as a is a potentially noninvasive and promising prognostic indicator for urothelial carcinoma; however, further studies with appropriate designs and larger sample sizes are needed to verify these findings.
本综述评估了全身免疫炎症指数（SII）在尿路上皮癌患者中的预后意义。
我们根据PRISMA标准对主要结局进行了系统评价和累积荟萃分析，并评估了研究质量。检索了七个数据库：Embase、PubMed、Cochrane图书馆、Web of Science、中国知网、万方和中国生物医学文献数据库，检索时间从各数据库创建至2024年10月。
荟萃分析纳入了31项研究，共14437例尿路上皮癌患者。低SII与更好的无复发生存期（RFS）（HR = 1.37，95%CI（1.19，1.56），P < 0.05）、癌症特异性生存期（CSS）（HR = 1.87，95%CI（1.50，2.34），P < 0.05）和总生存期（OS）（HR = 1.42，95%CI（1.23，1.64），P < 0.05）显著相关。此外，亚组分析发现，无论治疗方案、肿瘤类型或SII临界值如何，较高的SII均与较差的预后相关，且高SII是尿路上皮癌人群中的一个重要预后生物标志物。
低SII可能与更好的RFS、CSS和OS相关。SII可作为尿路上皮癌一种潜在的非侵入性且有前景的预后指标；然而，需要进一步开展设计合理、样本量更大的研究来验证这些发现。
